---
schema_version: "secwatch.filing_event.v1"
accession: "0001640334-24-001132"
form_type: "8-K"
ticker: "LEXX"
cik: "0001348362"
company_name: "Lexaria Bioscience Corp."
filed_at: "2024-07-17T23:59:59+00:00"
generated_at: "2026-05-31T20:10:18.531686+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Lexaria animal study interim results: DehydraTECH liraglutide and CBD show weight loss; CFO Cabatuan resigns

## Summary
- CFO Nelson Cabatuan resigned effective July 15; becomes Chief Strategic Financial Advisor; 150k unvested options expire, vested 50k options reduced to July 2026.
- In study WEIGHT-A24-1, DehydraTECH-CBD3 and DehydraTECH-liraglutide showed largest weight loss: -1.50% and -1.58% over 28 days.
- DehydraTECH works with semaglutide both with and without SNAC; pure semaglutide arm performed similarly to reformulated Rybelsus.
- Dosing in final four study arms (Cohort 2) began, combining DehydraTECH-semaglutide+CBD and DehydraTECH-liraglutide+CBD; results expected mid-October.
- Study is exploratory; not powered for statistical significance; blood glucose and PK data pending.

## SEC filing metadata
- accession: 0001640334-24-001132
- form_type: 8-K
- ticker: LEXX
- cik: 0001348362
- company_name: Lexaria Bioscience Corp.
- filed_at: 2024-07-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1348362/000164033424001132/0001640334-24-001132-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348362/000164033424001132/lxrp_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001640334-24-001132
- JSON: https://secwatch.observer/filing/0001640334-24-001132.json
- Plain text: https://secwatch.observer/filing/0001640334-24-001132.txt

## Key facts
- Executive change
  Nelson Cabatuan resigned as Chief Financial Officer at Lexaria Bioscience Corp..
  - Action: resigned
  - Role: Chief Financial Officer
  source text: Effective on July 15, 2024, Mr. Nelson Cabatuan resigned from his position as the Company’s Chief Financial Officer in order to focus his attention on corporate finance and strategic industry relationships for Lexaria as its Chief Strategic Financial Advisor.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1348362/000164033424001132/0001640334-24-001132-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.